Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 …
Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a …
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Background Despite advancements in care, many people with type 2 diabetes do not meet
treatment goals; thus, development of new therapies is needed. We aimed to assess …
treatment goals; thus, development of new therapies is needed. We aimed to assess …
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial
L Gao, BW Lee, M Chawla, J Kim, L Huo, L Du… - Nature Medicine, 2023 - nature.com
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight …
MA Nauck, DA D 'Alessio - Cardiovascular diabetology, 2022 - Springer
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type
2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered …
2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered …
Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized …
D Dahl, Y Onishi, P Norwood, R Huh, R Bray, H Patel… - Jama, 2022 - jamanetwork.com
Importance The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …
and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment …
Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial
J Rosenstock, JP Frías, HW Rodbard, S Tofé, E Sears… - Jama, 2023 - jamanetwork.com
Importance Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of …
peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy and safety of …
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 …
Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
[HTML][HTML] Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular …
Background Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose
and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy …
and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre …
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …
receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients …